can you take semaglutide and vyvanse (Lisdexamfetamine) for ADHD: Efficacy, Safety, What Patients Should Know GLP-1s & ADHD Meds: Safety,

The EFS rate at 2 years was 72% (95% confidence interval [CI], 64%80%) in the neoadjuvant-adjuvant group and 49% (95% CI, 41%59%) in the adjuvant-only group.[20][Level of evidence B1] At the time of data cutoff, 36 deaths (14 in the neoadjuvant-adjuvant group and 22 in the adjuvant-only group) were reported

2022;8(1):e08837

Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine

Eli Lilly and Company is pursuing a similar strategy with tirzepatide, its blockbuster dual GIP and GLP-1 therapy marketed as Mounjaro and Zepbound, by urging regulators to recognize the drugs complexity and the risks associated with large scale compounding